These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 27920704)

  • 41. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
    Seetharamu N; Preeshagul IR; Sullivan KM
    Lung Cancer (Auckl); 2017; 8():67-78. PubMed ID: 28761384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
    Zhao L; Yang Y; Li W; Li T; Gao Q
    Immunotherapy; 2018 Aug; 10(11):913-917. PubMed ID: 30149764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.
    Ogawa K; Ito J; Fujimoto D; Morita M; Yoshizumi Y; Ariyoshi K; Tomii K; Katakami N
    Invest New Drugs; 2018 Jun; 36(3):509-512. PubMed ID: 29340837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 49. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors.
    Lee J; Graham A; Sion A
    J Oncol Pharm Pract; 2019 Dec; 25(8):1867-1872. PubMed ID: 30651028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab.
    Schwab KS; Kristiansen G; Schild HH; Held SEA; Heine A; Brossart P
    Case Rep Oncol; 2018; 11(1):17-20. PubMed ID: 29515404
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
    Inokuchi J; Eto M
    Cancer Manag Res; 2019; 11():4519-4528. PubMed ID: 31191013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.
    Kong BY; Micklethwaite KP; Swaminathan S; Kefford RF; Carlino MS
    Melanoma Res; 2016 Apr; 26(2):202-4. PubMed ID: 26795275
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.
    Abdin SM; Zaher DM; Arafa EA; Omar HA
    Cancers (Basel); 2018 Jan; 10(2):. PubMed ID: 29370105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cold Autoimmune Hemolytic Anemia due to High-grade non Hodgkin's B cell Lymphoma with Weak Response to Rituximab and Chemotherapy Regimens.
    Nazel Khosroshahi B; Jafari M; Vazini H; Ahmadi A; Shams K; Kholoujini M
    Int J Hematol Oncol Stem Cell Res; 2015 Jul; 9(3):157-60. PubMed ID: 26261701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
    Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
    Vardhana S; Cicero K; Velez MJ; Moskowitz CH
    Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.